AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 133 min read$JNJ

Johnson & Johnson (JNJ) Shares Dip After Q3 Results and Raised 2

Johnson & Johnson (JNJ) shares fell 1.4% premarket after Q3 results. Revenue rose 5.9% to $25.4B, EPS beat estimates. JNJ raised full-year guidance, showing confidence. Dividend yield is 1.95% with a 55% payout ratio. GF Score is 83/100, but stock is 35.7% over GF Value. Insiders sold $154.9M in shares over 12 months.

Original reporting
gurufocus.com
Published Oct 13, 2026, 11:57 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 12:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$JNJ
Neutral
high confidence
Mentioned
$JNJ
Relevance
8/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$JNJNeutralHigh
01

Why it matters

The earnings beat and guidance raise are positive fundamentals, but the stock's premium valuation and insider selling create headwinds.

02

Market read

Earnings and guidance update for a mega‑cap health care stock; modest short‑term market impact expected.

03

What to watch

Insider net selling and guru trimming could signal underlying concerns despite earnings beat.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Johnson & Johnson reported Q3 2026 results, beating EPS estimates and raising full‑year guidance, while its dividend remains stable.

Company-level read

Ticker impact

$JNJNeutralHigh confidence
Context

Q3 2026 earnings released; revenue up 5.9% YoY, EPS $2.59 beating estimates, and full-year guidance raised to $11.05‑$11.15.

Expected impact

likely modest pressure as investors weigh higher valuation against guidance raise.

Evidence & confidence

Guidance lift is positive but stock already priced at a premium; short‑term sell pressure may persist.

Market effects

Sector

Healthcare sector may see modest uplift as a bellwether large‑cap raises guidance.

Regional

U.S. market sentiment could be slightly dampened by premium valuation concerns.

Global

Limited; impact confined to U.S. healthcare equities.

Counterpoint

What could challenge this read

The guidance raise may be undervalued; a pull‑back could present a buying opportunity at current dip.

Key entities

  • company
    Johnson & Johnson

    Large‑cap healthcare conglomerate reporting Q3 earnings.

Read at source← All news

StoryJohnson & Johnson posts Q3 2026 earnings, raises full‑year sales and EPS outlook despite one‑time charge

Also covered by

5 outlets

Related articles

OCT 13
$JNJHighAI 9/10

What Johnson & Johnson (JNJ) Said on Its Q3 Earnings Call

Johnson & Johnson (JNJ) reported Q3 sales growth across multiple drugs, including DARZALEX, CARVYKTI, and TECVAYLI. MedTech sales rose 2.5%, missing internal expectations. The company raised its full-year operational sales guidance to 6.7%-7.1% and expects $100.7B in operational sales. JNJ also announced a $5.5B proposed resolution for ovarian talc litigation and plans to spin off DePuy Synthes by mid-2027.

finance.yahoo.com7 min
OCT 13
$JNJMedAI 8/10

Johnson & Johnson Drops 5% as One-Time Charges Overshadow Raised Full-Year Outlook; Eli Lilly Dips, Pfizer Sits Out the Selloff

Johnson & Johnson (JNJ) stock fell 5% despite raising its full-year outlook due to one-time charges, including talc litigation. Q3 2026 revenue grew 5.9%, but reported net earnings dropped 95.9%. Eli Lilly (LLY) and Pfizer (PFE) also saw declines. JNJ's growth came from its Innovative Medicine division, while MedTech lagged. The company secured market authorization for its OTTAVA robotic surgical system and priority review for RYBREVANT FASPRO.

247wallst.com7 min
OCT 13
$JNJHighAI 8/10

Tremfya rescues J&J’s immunology sales to fuel strong Q3

Johnson & Johnson reported Q3 sales of $25.4bn, beating estimates. Tremfya's sales surged 68.3% to $2.4bn, driving a 7.9% increase in the pharma segment. Overall immunology sales grew 1.3%, offset by declines in Stelara, Remicade, and Simponi. J&J raised its 2026 sales and EPS guidance, despite lower Q3 EPS due to acquisitions and legal settlements. Medtech sales grew 2.5%, led by Shockwave's 16.8% increase.

finance.yahoo.com2 min
OCT 13
$JNJMedAI 8/10

Johnson & Johnson raises 2026 guidance as quarterly sales climb

Johnson & Johnson (JNJ) raised its 2026 sales and earnings forecasts after Q3 sales grew 6%. Full-year sales midpoint increased to $101.2B, and adjusted EPS midpoint rose by $0.06 to $11.10. Q3 sales reached $25.4B, with adjusted EPS at $2.59. Growth was driven by Innovative Medicine and MedTech divisions, while Stelara sales declined. Shares fell over 5% on the news.

finance.yahoo.com2 min